CNS Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 15, 2024. The unaudited statements are prepared under U.S. GAAP.
Business context
CNS Pharmaceuticals is a clinical-stage drug developer focused on cancers of the brain and central nervous system. Its lead candidate, Berubicin, is being evaluated in a randomized Phase 2 trial for glioblastoma. The company reported no revenue for the period and depends on external financing to fund operations and development.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| General and administrative expense | $1.114 million | $1.359 million |
| Research and development expense | $2.430 million | $3.568 million |
| Total operating expenses | $3.545 million | $4.927 million |
| Net loss | $3.545 million | $4.932 million |
| Basic and diluted loss per share | $0.41 | $2.59 |
| Net cash used in operating activities | $3.192 million | $4.825 million |
| Cash and cash equivalents at period end | $815,226 | $5.111 million at March 31, 2023 |
At March 31, 2024, current assets were $1.601 million and current liabilities were $6.091 million, producing a working-capital deficit of approximately $4.490 million. Total liabilities were $6.091 million; notes payable were $213,104. Stockholders’ deficit was $4.431 million. No operating margin is meaningful because the company reported no revenue.
Changes and financing
- Net loss fell by approximately $1.387 million year over year, primarily due to lower clinical-trial-related R&D spending and lower legal and professional expenses. Management attributed the R&D decrease mainly to timing of CRO costs and expects trial costs to increase as development continues.
- In February 2024, the company completed an offering of common stock and warrants. It reported approximately $4.0 million gross proceeds and $3.331 million net proceeds after offering costs. Financing cash flow was $3.459 million, including stock-sale and warrant-exercise proceeds, partly offset by note repayments.
- Shares issued and outstanding rose from 6.215 million at December 31, 2023 to 10.669 million at March 31, 2024. The company had 39.786 million warrants outstanding at quarter-end. On May 15, 2024, 11.852 million common shares were outstanding.
Outlook, risks, and unusual items
- Going concern and funding: Management says cash is expected to fund operations only into the latter half of Q2 2024 and that substantial additional capital is required. It estimates $13–15 million of additional financing to complete the potentially pivotal Berubicin Phase 2 trial, in addition to working capital needs estimated at $4.5–5.0 million annually. A further $5 million would be needed for near-term WP1244/WP1874 development. The filing states that substantial doubt exists about the company’s ability to continue as a going concern.
- Clinical program: The Berubicin trial plans to enroll 252 patients and compare Berubicin with Lomustine. The DSMB recommended in December 2023 that the study continue without modification; management remains blinded to the underlying data. Trial completion, results, regulatory approval, and commercial success are uncertain.
- Nasdaq listing: The company had notices concerning minimum stockholders’ equity and bid-price requirements. On May 6, 2024, Nasdaq granted an extension to July 15, 2024 to demonstrate compliance. The company says its plan requires significant financing for which it has no commitments; failure to comply could result in delisting.
- Licenses: UTMDACC notified the company on April 25, 2024 of intent to terminate the WP1244 license unless $50,000 in maintenance fees and $1,300 in expenses are paid; the company had not decided whether to cure the defaults as of the filing. The company also gave HPI notice on May 14 of its intent to terminate the HPI license effective on or about July 14, stating it does not believe termination will prevent continued Berubicin development because the licensed patents have expired.
- Controls: Management concluded disclosure controls were ineffective due to material weaknesses involving segregation of duties, timely and complete CRO cost information, and documentation of the control environment. The company reported additional review procedures and plans to improve controls.
- Post-quarter capital structure: On May 2, the company increased authorized common shares from 75 million to 300 million. After quarter-end, investors exercised 1.183 million warrants exercisable at $0.001 per share. These changes may facilitate financing but could increase dilution.
Important facts for investors to verify
- Cash runway, financing availability, and whether the company can meet near-term obligations and fund the Berubicin trial.
- Nasdaq compliance milestones and status before the July 15, 2024 deadline.
- Whether the WP1244 license defaults were cured and the eventual status of the HPI license.
- Berubicin trial enrollment, timing, and future clinical updates, noting the DSMB recommendation is not a disclosure of efficacy results.
- Potential dilution from outstanding warrants, options, subsequent exercises, and the expanded authorized share count.